HALIX Joins Consortium of Partners to Provide GMP Services for COVID-19 Vaccine

April 16, 2020

Dutch company HALIX has announced it is joining a consortium of partners that are all under the guidance of the University of Oxford to provide good manufacturing practice (GMP) manufacturing services for a COVID-19 vaccine.

Dutch company HALIX has announced it is joining a consortium of partners that are all under the guidance of the University of Oxford to provide good manufacturing practice (GMP) manufacturing services for a COVID-19 vaccine.

The alliance will support the large-scale production of a COVID-19 vaccine that is currently under development at the University of Oxford’s Jenner Institute. As part of the collaboration, HALIX will use its GMP facilities, applying its viral vector bioprocessing expertise, to transfer an industrial scale drug substance from Pall in the United Kingdom. Through the ability to manufacture at a larger scale, it is possible that the time to make the vaccine available for deployment could be decreased.

In an April 15, 2020 press release, Alex Huybens, chief operations officer of HALIX, said, “We are committed to working as one team across the industry bringing our collective expertise, track record, and manufacturing capabilities, to support the Jenner Institute’s rapid clinical development of this nCoV-19 vaccine candidate to combat this evolving crisis as quickly as possible.”

Source: HALIX